Evidence map›Paper›PMID 31700590›Full record

ArticleMediterranean journal of hematology and infectious diseases2019

Diagnostic Performance and Safety of Bronchoalveolar Lavage in Thrombocytopenic Haematological Patients for Invasive Fungal Infections Diagnosis: A Monocentric, Retrospective Experience.

Mariagiovanna Cefalo, Ermanno Puxeddu, Loredana Sarmati, Giovangiacinto Paterno, Carla Fontana, Daniela Nasso, Gloria Pane, Eleonora De Bellis, Raffaele Palmieri, Elisa Buzzati and 12 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Mediterranean journal of hematology and infectious diseases, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
1.0field-weighted citation impact, top 24% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 11 citations in OpenAlex.

  1. Article
  2. Impact of posaconazole prophylaxis and antifungal treatment on BAL GM performance in hematology malignancy patients with febrile neutropenia: a real life experience.European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology · 2024
    Article
  3. Article
  4. Article
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

22 authors at 1 institution in 1 country.

Mariagiovanna CefaloHematology, Department of Biomedicine and Prevention, University of Rome "Tor Vergata", Rome, Italy.
Ermanno PuxedduDivision of Respiratory Medicine, Department of Experimental Medicine and Surgery, University of Rome "Tor Vergata", Rome, Italy.
Loredana SarmatiClinical Infectious Diseases, Department of Systems Medicine, University of Rome "Tor Vergata", Rome, Italy.
Giovangiacinto PaternoHematology, Department of Biomedicine and Prevention, University of Rome "Tor Vergata", Rome, Italy.
Carla FontanaClinical Microbiology Laboratories, Department of Experimental Medicine, Tor Vergata University of Rome, Rome, Italy.
Daniela NassoHematology, Department of Biomedicine and Prevention, University of Rome "Tor Vergata", Rome, Italy.
Gloria PaneDivision of Respiratory Medicine, Department of Experimental Medicine and Surgery, University of Rome "Tor Vergata", Rome, Italy.
Eleonora De BellisHematology, Department of Biomedicine and Prevention, University of Rome "Tor Vergata", Rome, Italy.
Raffaele PalmieriHematology, Department of Biomedicine and Prevention, University of Rome "Tor Vergata", Rome, Italy.
Elisa BuzzatiHematology, Department of Biomedicine and Prevention, University of Rome "Tor Vergata", Rome, Italy.
Federico MeconiHematology, Department of Biomedicine and Prevention, University of Rome "Tor Vergata", Rome, Italy.
Roberta LaureanaHematology, Department of Biomedicine and Prevention, University of Rome "Tor Vergata", Rome, Italy.
Paola CascianiHematology, Department of Biomedicine and Prevention, University of Rome "Tor Vergata", Rome, Italy.
Anna Giulia ZizzariHematology, Department of Biomedicine and Prevention, University of Rome "Tor Vergata", Rome, Italy.
Paola RoglianiDivision of Respiratory Medicine, Department of Experimental Medicine and Surgery, University of Rome "Tor Vergata", Rome, Italy.
Paolo de FabritiisHematology, Department of Biomedicine and Prevention, University of Rome "Tor Vergata", Rome, Italy.
Luca MaurilloHematology, Department of Biomedicine and Prevention, University of Rome "Tor Vergata", Rome, Italy.
Francesco BuccisanoHematology, Department of Biomedicine and Prevention, University of Rome "Tor Vergata", Rome, Italy.
Maria CantonettiHematology, Department of Biomedicine and Prevention, University of Rome "Tor Vergata", Rome, Italy.
William ArceseHematology, Department of Biomedicine and Prevention, University of Rome "Tor Vergata", Rome, Italy.
Adriano VendittiHematology, Department of Biomedicine and Prevention, University of Rome "Tor Vergata", Rome, Italy.
Maria Ilaria Del PrincipeHematology, Department of Biomedicine and Prevention, University of Rome "Tor Vergata", Rome, Italy.
University of Rome Tor Vergata · IT

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundAlthough bronchoalveolar lavage (BAL) measurements of galactomannan antigen (GM) seems to be more sensitive than serum testing to detect invasive fungal infection (IFI), a consensus on the most appropriate diagnostic threshold of the BAL GM test is still unclear. Moreover, there is uncertainty as to whether BAL is a safe procedure in patients with hematological malignancies (HM) and thrombocytopenia.

objectivesBased on this background, 102 adult patients with HM and associated thrombocytopenia were retrospectively analyzed with the dual aim of 1) determining whether BAL is a safe and feasible procedure; and, 2) identifying the most appropriate threshold for GM positivity in the diagnosis of IFI. PATIENTS/

methodseach BAL was considered as one case/patient. One hundred twelve BALs were carried out in 102 HM patients: at the time of the BAL, the median platelet count (PLTs) in all patients was 47×10

resultscomplications from the BAL were infrequent (3.5%) and mild. No bleeding was reported. The BAL GM cut off of >0.8 was associated with the best diagnostic accuracy (sensitivity 72.97% and specificity 80%). Antifungal treatment of patients with BAL GM >0.8 resulted in a clinical-radiological improvement in 35/41 patients (85%).

conclusionsBAL was a safe procedure also in thrombocytopenic patients, permitting an IFI diagnosis not otherwise identifiable using EORTC/MSG criteria. Our data suggest that a BAL GM value of>0.8 represents the most useful cut-off in terms of sensibility and specificity. Further prospective studies on a more significant number of patients are needed to confirm these results.

Indexed as

Bronchoalveolar lavageGalactomannan antigenHematologic malignanciesPulmonary aspergillosisThrombocytopenia

Identifiers

PMID31700590
PMCPMC6827601
OpenAlexW2983274304

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.